Currently, heart failure affects 1-2% of the over-65-year old population and has a 5-year fatality rate of over 40%. Current therapies involve serious surgeries such as mechanically-assisted heart device implantation or heart transplantation. Some of the drawbacks to these approaches are death or complications related to the surgery itself, failure to improve the patient state, repeated surgeries to replace a heart device or failing transplant, and life on immunosuppressant for heart transplant recipients. Furthermore these therapies improve heart function, but don’t cure the heart since the damaged heart muscle is not regenerated or replaced. Finally, the estimated direct and indirect cost of heart failure alone for 2007 was $33.2 billion.
ChemRegen’s approach is a “first in class” drug development approach that if successful would change the future of cardiac medicine. The innovative approach presented herein: mobilization of endogenous stem or progenitor cells directly in the patient’s heart for regeneration by stimulation with small molecules has many advantages including no invasive intervention and lower death rate related to treatment. It is a cure as the ailing heart would be regenerated using “dormant” stem or progenitor heart cells. It would not involve surgery, implanted devices or exogenous transplant and lifelong immunosuppressant treatment. Treatment would be administered under the form of a pill or injection which typically does not require hospitalization and all the cost associated with hospitalization.